Dr. Fertrin on the Potential of Fostamatinib in Chronic ITP

Kleber Y. Fertrin, MD, PhD
Published: Monday, Jul 29, 2019



Kleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, and hematology oncologist, Seattle Cancer Care Alliance, discusses the potential of fostamatinib (Tavalisse) in the treatment of patients with chronic immune thrombocytopenia (ITP).

Fostamatinib is the first Syk inhibitor that was developed for the treatment of patients with chronic ITP. The agent was approved by the FDA in 2018 for use as a second-line therapy in patients with chronic ITP following an insufficient response to prior therapy. The approval was based on findings from 2 randomized trials and 1 open-label extension study. Notably, the agent has shown a response rate of approximately 30% in patients who are refractory to 2, or potentially 3, prior therapies.

However, many questions remain with the agent, explains Fertrin, such as whether or not the agent can be combined with other therapies. Additionally, although the agent has shown activity in a heavily pretreated population, it is unclear whether it will possess the same activity in earlier lines of treatment, says Fertrin. Many clinical trials with fostamatinib in heavily pretreated and treatment-naïve patients with chronic ITP are anticipated.
SELECTED
LANGUAGE


Kleber Y. Fertrin, MD, PhD, assistant professor, University of Washington School of Medicine, and hematology oncologist, Seattle Cancer Care Alliance, discusses the potential of fostamatinib (Tavalisse) in the treatment of patients with chronic immune thrombocytopenia (ITP).

Fostamatinib is the first Syk inhibitor that was developed for the treatment of patients with chronic ITP. The agent was approved by the FDA in 2018 for use as a second-line therapy in patients with chronic ITP following an insufficient response to prior therapy. The approval was based on findings from 2 randomized trials and 1 open-label extension study. Notably, the agent has shown a response rate of approximately 30% in patients who are refractory to 2, or potentially 3, prior therapies.

However, many questions remain with the agent, explains Fertrin, such as whether or not the agent can be combined with other therapies. Additionally, although the agent has shown activity in a heavily pretreated population, it is unclear whether it will possess the same activity in earlier lines of treatment, says Fertrin. Many clinical trials with fostamatinib in heavily pretreated and treatment-naïve patients with chronic ITP are anticipated.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Publication Bottom Border
Border Publication
x